
-
Galecto NasdaqCM:GLTO Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Location: Ole Maaloes Vej 3, Copenhagen, 2200, Denmark | Website: https://galecto.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-6.248M
Cash
11.94M
Avg Qtr Burn
-3.782M
Short % of Float
4.56%
Insider Ownership
3.59%
Institutional Own.
13.05%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
GB1211 (oral galectin-3 inhibitor) + pembrolizumab (Keytruda®) Details Cancer, Head and neck squamous cell carcinoma, Melanoma | Phase 2 Data readout | |
GB1211 (oral galectin-3 inhibitor) Details Cirrhosis, Non-alcoholic steatohepatitis | Phase 2 Update | |
GB1211 (oral galectin-3 inhibitor) + TECENTRIQ Details Non-small cell lung carcinoma, Cancer, Fibrosis | Phase 2a Update | |
GB3226 (formerly BRM-1420) Details Acute myeloid leukemia, Blood cancer, Cancer | IND Submission | |
GB2064 (oral LOXL2 inhibitor) Details Fibrosis, Myelofibrosis | Failed Discontinued | |
GB0139 (inhaled galectin-3 inhibitor) Details Fibrosis, Pulmonary fibrosis, Lung disease, Idiopathic pulmonary fibrosis | Failed Discontinued |